Introduction {#Sec1}
============

Multiple sclerosis (MS) is an inflammatory demyelinating disorder in which the myelin sheaths surrounding nerve fibers in the central nervous system (CNS) are damaged. The immune-mediated damage disrupts communication between the brain and the rest of the body, leading to symptoms such as numbness, visual dysfunction, weakness, gait difficulty, bowel and bladder dysfunction, and cognitive impairment. Relapsing/remitting disease course is the most common (85%), with isolated attacks of new or increasing neurological symptoms \[[@CR29]\]. The primary progressive form, seen in around 10--15% of MS patients, is characterized by worsening neurological function from symptom onset, without relapses or remission \[[@CR43]\]. Among patients with relapsing/remitting MS (RRMS), there is a subset of patients with highly active MS. Such patients are characterized by frequent relapses with incomplete recovery, high burden of radiological lesions, and rapid disability worsening \[[@CR32], [@CR42]\].

The exact cause of MS is still unknown; however, genetic and environmental factors are believed to play a role. Multiple mechanisms of immune-mediated injury to myelin and oligodendrocytes have been proposed, such as cytokine-mediated injury, complement-mediated injury, antibody-mediated cytotoxicity, and direct injury to oligodendrocytes by CD4+ and CD8+ T cells \[[@CR36]\]. Since T and B lymphocytes and cytokines play important roles in the pathogenesis of MS, immune therapies targeting these lymphocytes and cytokines can achieve better treatment outcomes. However, therapies differ in their ability to penetrate the blood brain barrier and act locally on inflammation and neurodegeneration in the CNS compartment \[[@CR1], [@CR6]\]. The search for new treatments aims at increasing benefits by increasing the anti-inflammatory activity in the CNS compartment while reducing treatment-limiting adverse effects and high treatment burden \[[@CR7], [@CR47], [@CR51]\].

In the past 25 years or so, many disease-modifying drugs (DMDs) have been approved for RRMS. Such DMDs include interferon-beta, glatiramer acetate, teriflunomide, dimethyl fumarate, natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab. These drugs exert their anti-inflammatory effects through various mechanisms \[[@CR35]\].

The objective of this article is to discuss opinions of MS experts in the Gulf region on the use of high-efficacy DMDs in the clinical practice. This discussion was focused on the following high-efficacy DMDs: natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab. Nine experts from the Gulf region with expertise in MS treatment were part of the discussion sessions. The experts were selected based on their years of expertise in managing MS patients.

Overview of High-Efficacy DMDs Used in RRMS {#Sec2}
===========================================

Natalizumab {#Sec3}
-----------

Natalizumab was the first monoclonal antibody approved to treat MS (in the United States \[USA\] in 2004 and in the European Union \[EU\] in 2006). Natalizumab prevents the migration of immune cells into the CNS by selectively binding to and inhibiting the very late antigen-4 (VLA-4) integrins \[[@CR41]\]. Natalizumab is indicated as monotherapy in adults with highly active RRMS. It is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS therapy \[[@CR49]\]. Natalizumab is administered as an intravenous (IV) infusion once every 4 weeks \[[@CR49]\]. In a phase III trial in patients with RRMS (AFFIRM trial), natalizumab reduced the annualized relapse rate (ARR) by 68% (*p* \< 0.001) and the disability progression rate by 42% (*p* \< 0.001) compared with placebo over 2 years \[[@CR39]\]; in another trial, it significantly improved magnetic resonance imaging (MRI) outcomes versus placebo over 2 years \[[@CR33]\].

Natalizumab is generally well-tolerated; however, it increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain, that usually causes death (23% mortality rate) or severe disability \[[@CR46], [@CR49]\]. By the end of 2017, around 756 people (out of over 180,000 people across the world taking natalizumab) had developed PML. It is therefore recommended that patients treated with natalizumab should be regularly screened for the risk of PML development using clinical vigilance, periodic MRI brain, and anti-John Cunningham virus (JCV) antibody. Presence of anti-JCV antibodies, prolonged treatment duration, and previous use of immunosuppressive therapy increase the risk of PML \[[@CR19]\]. In patients who are at high risk for the development of PML, discontinuation of natalizumab is considered; however, this may trigger severe rebound with clinical and radiological worsening. Therefore, close monitoring with a short washout phase is recommended after natalizumab withdrawal \[[@CR19]\]. Clinically significant liver injury has been reported in patients treated with natalizumab in the post-marketing setting \[[@CR3]\]. Other potential serious risks associated with natalizumab include infusion reactions, and rare, serious opportunistic infections, especially PML. Appropriate patient selection by a thorough understanding of individual risk factors for PML and other adverse events can prove beneficial for optimizing treatment with natalizumab in RRMS patients \[[@CR46]\].

Fingolimod {#Sec4}
----------

Fingolimod is the first oral drug for MS, approved in the USA in 2010 and in the EU in 2011. It is an immunosuppressive agent that blocks the egress from the lymph nodes to the CNS by its action on sphingosine 1-phosphate (S1P) receptors \[[@CR4], [@CR5], [@CR31], [@CR38]\]. However, fingolimod does not affect lymphocyte function \[[@CR31]\]. Fingolimod has been shown to be superior to placebo (over 2 years) and interferon β-1a (IFNβ-1a; over 1 year) in terms of reduction in the ARR and brain lesions in RRMS patients \[[@CR8], [@CR23]\]. Moreover, fingolimod was superior to placebo for reducing the risk of disability progression; however, it was equivalent to IFNβ-1a \[[@CR8]\].

The most common adverse events reported with fingolimod in clinical trials and in a real-world setting include infections such as influenza and sinusitis \[[@CR13], [@CR15]\]. Cases of bradyarrhythmia and atrioventricular (AV) blocks have been reported in patients treated with fingolimod; therefore, patients should be monitored during treatment initiation \[[@CR50]\]. On having to restart fingolimod after discontinuation for more than 14 days after the first month of treatment, similar monitoring is recommended \[[@CR15]\]. Macular edema has been reported in patients treated with fingolimod; hence, a follow up ophthalmological examination is recommended 4--6 months after initiation of treatment \[[@CR24]\]. In patients with pre-existing heart conditions, or in diabetic patients who may at higher risk of developing macular edema, benefits of fingolimod should be weighed against its risks before initiating fingolimod therapy. Risk of PML is low with fingolimod; of the more than 200,000 fingolimod-treated patients worldwide, as of August 2017, 15 patients developed PML in the absence of natalizumab treatment in the preceding 6 months \[[@CR2]\]. Cases of disease reactivation have been reported in patients who discontinued fingolimod \[[@CR44]\].

A meta-analysis of 25 real-world studies of fingolimod found that an average of 82% of patients continued with fingolimod treatment for 1 year \[[@CR22]\], which indicates good treatment adherence.

Alemtuzumab {#Sec5}
-----------

Alemtuzumab is a recombinant humanized monoclonal antibody, approved for RRMS in the USA in 2014 and in the EU in 2013. Alemtuzumab is a CD52-directed cytolytic monoclonal antibody; it reduces the levels of circulating T and B lymphocytes. Alemtuzumab is indicated for adults with RRMS with active disease. It is administered as an IV infusion for two initial treatment courses (first treatment course: 5 consecutive days; second treatment course: administration on 3 consecutive days 12 months after first course) and subsequent additional treatment courses after at least 1 year from the second infusion, if required \[[@CR28]\]. In clinical trials, alemtuzumab significantly reduced ARR and new brain lesions as compared to IFN β-1a over 2 years in patients with RRMS \[[@CR9], [@CR10]\].

The most common adverse event reported with alemtuzumab is infusion-related reactions, for which monitoring and administration of symptomatic treatment are recommended \[[@CR45]\]. Autoimmune thyroiditis, a serious adverse event, is seen in approximately 30% of patients taking alemtuzumab. Autoimmune thyroiditis is typically at its peak during the third year of treatment with alemtuzumab. Clinical vigilance along with monitoring of thyroid-stimulating hormone (TSH) and thyroid antibodies every 3 months is recommended as a precautionary measure for autoimmune thyroiditis. Other autoimmune adverse events associated with alemtuzumab include immune thrombocytopenia and glomerulonephritis. Alemtuzumab also increases the risk of malignancies, including thyroid cancer \[[@CR27]\]. A risk management plan which entails clinical vigilance and monthly laboratory monitoring for platelets, renal function testing, and urinalysis is recommended. Recently, the US Food and Drug Administration (FDA) has issued a notice citing rare but serious cases of stroke and tears in the lining of head and neck reported in 13 patients receiving alemtuzumab. According to the FDA, this adverse event can lead to permanent disability and even death (FDA Safety Announcement. Drug safety and availability---FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada \[[@CR12]\] \[WWW Document\] 2018). Furthermore, infrequent cases of listeria infection have been reported with alemtuzumab, for which use of prophylactic antibiotics with each course of infusion is recommended by experts \[[@CR40]\]. Because of its safety profile, the use of alemtuzumab is restricted to patients with either highly active disease or patients who have had an inadequate response to previous DMDs indicated for the treatment for MS \[[@CR27]\].

Cladribine tablets {#Sec6}
------------------

Cladribine tablets are orally administered drugs, approved in the EU in 2017. Oral cladribine has not yet been approved for RMS. Cladribine is a structural analogue of deoxyadenosine; preferential accumulation of cladribine phosphates interferes with DNA synthesis and repair, ultimately resulting in DNA strand breaks and cell death \[[@CR26]\]. Cladribine is given orally as tablets in two short courses 1 year apart. No active treatment is required in year 3 and 4. Cladribine tablets are indicated for adults with highly active RMS as defined by clinical and radiological features \[[@CR30]\]. In clinical trials, cladribine tablets significantly reduced the ARR, probability of disability progression, and brain lesions as compared to placebo over 96 weeks in patients with RRMS \[[@CR11], [@CR16], [@CR17]\]. The most common adverse event associated with cladribine tablets is lymphopenia \[[@CR30]\]. A resultant depletion in the body's immune cells can increase the risk of infections and malignancies. Patients with lymphocyte counts below 500 cells/mm^3^ should be actively monitored for signs and symptoms suggestive of infections \[[@CR30]\]. Among MS patients treated with cladribine (1976 patients), no case of PML has been reported \[[@CR30]\]. As cladribine tablets have been approved recently, real-world evidence data is limited \[[@CR48]\][1](#Fn1){ref-type="fn"}.

Ocrelizumab {#Sec7}
-----------

Ocrelizumab is a recombinant humanized monoclonal antibody, approved in the USA in 2017 and in the EU in 2018. Ocrelizumab binds to the cell surface antigen CD20 and selectively reduces the number and function of B cells. Ocrelizumab is indicated in adults with active relapsing or primary progressive forms of MS. It is administered as an IV infusion \[[@CR37]\]. In clinical trials, ocrelizumab significantly reduced the ARR, probability of disability progression, and brain lesions as compared to IFN β-1a over 96 weeks in patients with relapsing MS \[[@CR20]\]. The most common and important adverse events associated with ocrelizumab are infusion-related reactions and infections \[[@CR37]\]. As ocrelizumab is a recently approved drug, limited real-world data are available \[[@CR34]\].

Expert Opinion {#Sec8}
==============

A workshop that included a total of nine MS experts from the Gulf region (Oman, United Arab Emirates, Qatar, Bahrain, and Kuwait) was organized to discuss individual opinions on the use of DMDs in clinical practice. The experts were chosen to be part of the advisory board based on their years of clinical experience in treating MS.

Before the workshop, a panel of these experts reviewed literature that included results of pivotal trials, meta-analyses, real-world evidence studies, and opinions/notifications of the licensing authorities (FDA/European Medicines Agency). The panel selected five DMDs (natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) and several criteria pertaining to these DMDs that should be discussed in the workshop, in order to reach an opinion on the use of high-efficacy DMDs in MS patients. These criteria were related to efficacy, safety, and convenience, including monitoring and adherence.

In the workshop, all the experts were first presented with latest information about the selected five DMDs. Following this presentation, questions were presented to the experts as part of a voting process. The questions ranged from efficacy of various DMDs, to those analyzing their safety and convenience. Experts used an online voting application/web-based audience response system from their smartphones and clicked the most appropriate responses based on their clinical experience. The compiled responses were shown in real time on their smartphone screens. This was followed by a discussion to validate their response. If there was a change of opinion based on the discussion, a re-voting was done.

For an efficacy attribute ("reduces disease activity overall"), the experts ranked the DMDs in order (Table [1](#Tab1){ref-type="table"}).Table 1DMD ranking based on efficacy attribute 'reduces disease activity overall' by expertsEfficacy attributeRanking12345Reduces disease activity overallAlemtuzumabCladribine tabletsOcrelizumabNatalizumabFingolimod*DMD* disease-modifying drug

The experts also rated the DMDs based on safety (Table [2](#Tab2){ref-type="table"}) and convenience (Table [3](#Tab3){ref-type="table"}) attributes by giving a ranking out of 10. Natalizumab scored highest for "availability of long-term safety data"; and cladribine tablets for "low risk of malignancy", "good benefit vs. risk profile", "good short- and long-term safety profile", and "low risk of PML". Ocrelizumab scored highest for being "relatively well tolerated". Regarding the convenience attributes, cladribine tablets scored highest for "convenient route and dosing schedule" and "low monitoring burden", while alemtuzumab scored highest for "good patient compliance". Overall, for the safety and convenience attributes, there was no single drug which scored highest for all the attributes, and the scoring varied based on the attribute.Table 2DMD ranking on safety attributes by experts (higher scores indicate better ranking)Safety attributesScoringCladribine tabletsFingolimodNatalizumabOcrelizumabAlemtuzumabAvailability of long-term safety data7.56.58.17.27.2Low risk of malignancy7.36.66.46.85.8Good benefit vs. risk profile7.45.77.36.96.2Good short- and long-term safety profile7.75.86.76.85.8Low risk of PML7.95.95.47.26.8Relatively well tolerated7.56.87.07.86.2*DMD* disease-modifying drug, *PML* progressive multifocal leukoencephalopathy Table 3DMD ranking on convenience attributes by experts (higher scores indicate better ranking)Convenience attributesScoringCladribine tabletsFingolimodNatalizumabOcrelizumabAlemtuzumabConvenient route and dosing schedule8.78.07.57.88.1Good patient compliance8.07.38.07.88.3Low monitoring burden8.06.77.57.25.9*DMD* disease-modifying drug

Discussion {#Sec9}
==========

The opinions and scorings discussed in this review are based on years of clinical experience regarding the usage of DMDs for MS treatment by Gulf region experts. No single drug scored highest for all the attributes, as the preference for the drugs varied based on the efficacy, safety, and convenience attributes. Alemtuzumab was ranked highest for 'reducing overall disease activity', while cladribine tablets scored highest for 'good benefit vs. risk profile'. For convenience attributes, oral DMDs including cladribine tablets and fingolimod were more favored for their convenient route and dosing schedule and low monitoring burden.

The expert panel discussed the difficulty in directly comparing the efficacy and safety of DMDs for RRMS. There is a difference between the clinical trials of new and old DMDs in different patient populations; for instance, baseline ARR in both treatment and control arms is different in these trials. Since diagnostic techniques for MS have evolved over the years, it is likely that these clinical trials also differ in the type of MS patient populations studied. Additionally, there are methodological differences (e.g., use of different comparators) across these clinical trials. More importantly, efficacy and safety data available for each DMD differs based on timespan of the DMD in the market; for example, plenty of long-term post-marketing data are available for natalizumab, but no long-term data are available for the recently approved ocrelizumab and cladribine tablets. In the absence of head-to-head clinical trials for the newer DMDs, comparative efficacy analyses using propensity score matching may be a valid approach, despite its potential bias. Furthermore, clinical experience with these DMDs is also valuable in corroborating the findings from clinical studies and shaping future opinions regarding DMDs' perceived benefits.

All available DMDs have demonstrated through clinical trials that they reduce the frequency and severity of relapses, reduce the development of new brain lesions, and slow the progression of disability in relapsing forms of MS, to varying extents. Ocrelizumab is the only drug which has demonstrated efficacy in both relapsing and primary progressive forms of MS; alemtuzumab and cladribine have not been known to be used for primary-progressive MS. Considering overlapping efficacy profiles of the drugs, safety and convenience attributes based on individual risk factors and patient preferences are an important part of treatment decision-making.

The definition of high-efficacy DMDs was used by MS experts in order to guide the treating neurologists on how to manage patients with highly active disease. Although there is no established consensus on the definition of highly active patients, it is generally accepted that those who have two or more relapses in 1 year or those who failed (or had suboptimal response) first-line therapies are considered adequate candidates for high-efficacy DMDs. Alemtuzumab and cladribine tablets are drugs for which patients who had a sub-optimal response were assessed in a clinical trial \[[@CR10]\]. On contrary, natalizumab and fingolimod have not been tested in such a population in clinical trials, but yet these drugs are used in such patients in clinical practice with good efficacy \[[@CR14]\]. Post-hoc analysis for ocrelizumab \[[@CR21], [@CR25]\] and cladribine \[[@CR18]\] showed similar results in patients with suboptimal response; however, these results should be interpreted with caution. Considering the high scores given to ocrelizumab and cladribine tablets in the workshop for efficacy, safety, and convenience attributes, they seem to be promising drugs in the treatment of highly active MS patients. However, long-term data for these newly approved DMDs are needed to show the presumed sustained effectiveness in such patient group.

The safety of DMDs was considered a very important attribute by the panel, especially with regards to selection of these DMDs for a specific group of patients. For example, it is advised to not use fingolimod in MS patients with cardiac disease or diabetic retinopathy. Similarly, patients with high anti-JCV titers (\> 1.5) are advised not to use natalizumab, while alemtuzumab should not be used in MS patients who have other autoimmune disorders. Long-term safety data of the newly approved DMDs, such as ocrelizumab and cladribine are not yet available; hence vigilance should be done when using such DMDs.

Patient's convenience is another attribute, which plays an important role while discussing treatment options with the patient. Certainly, oral DMDs such as fingolimod and cladribine tablets seem to be a very attractive option to patients; however, a few physicians and patients may consider DMDs that have less frequent dosing as a more convenient option; such DMDs include alemtuzumab (yearly course for 2 years) and ocrelizumab (6-month course). Cladribine tablets offer both, benefits of less frequent dosing and the oral route, and this may explain why it was scored high by the panel. When discussing convenience, the burden of monitoring may play an important role, as DMDs with frequent laboratory monitoring (e.g. alemtuzumab) may be less appealing to patients and sometimes physicians.

Conclusion {#Sec10}
==========

All DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration.

Cladribine described across the article refers to the oral formulation, Cladribine tablets.
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